COPENHAGEN--8 May--PRNewswire-AsiaNet/InfoQuest New Data Show Clear Benefit of Protelos(R) in Wide Range of Osteoporosis Patients Irrespective of Disease Severity New, long term data presented at the 34th European Symposium on Calcified Tissues (ECTS) this week underscore the unmatchable, long-term efficacy and quality of life improvement offered by the anti-osteoporotic treatment, Protelos(R) (strontium ranelate). These data also provide evidence to show that Protelos has clinical benefit in a broad range of osteoporotic patients,irrespective of their level of bone turnover and severity of their disease. Protelos is a new anti-osteoporosis treatment with a unique mode of action both increasing bone formation and decreasing bone resorption. For the first time, new data have shown sustained, five year efficacy against vertebral and non-vertebral fractures, including hip fractures (1). Protelos is also the first treatment to show an improvement in the quality of life of patients withvertebral postmenopausal osteoporosis over four years(2). Five year efficacy(1) Five year data on the long term antifracture efficacy of Protelos from the TROPOS (TReatment Of Peripheral OSteoporosis) study show that, uniquely for an anti-osteoporotic treatment, Protelos provides sustained five year efficacy against vertebral, non vertebral and hip fractures. The phase III study, run across 75 European and Australian centres involved over 5,000 women withpostmenopausal osteoporosis with mean age of 76 given either 2g daily of Protelos or placebo for five years. All patients also received calcium and vitamin D supplements according to their needs. The five year results revealed a 24% reduction in vertebral fracture (p